

**Overall Certificate**  
**For Financial Statements**  
**Section 347 (2)(b), Companies Act 2014**


**Company Name: Collon Pharmacy Limited**

**Company Number: 404912**


**Financial Year: 1 August 2024 to 31 July 2025**

**CERTIFICATE:**

We hereby certify that all financial statement documents which are required under Part 6 of the Companies Act 2014 to be annexed to this annual return, have been so annexed, and that they are true copies of the originals, or information extracted from the originals, laid or to be laid before the relevant general meeting, or presented to the member(s).

  
\_\_\_\_\_  
Emma Fitzsimmons  
Director

16 December 2025

  
\_\_\_\_\_  
Anthony Fitzsimmons  
Secretary

16 December 2025

\_\_\_\_\_

Company Number: 404912

**Collon Pharmacy Limited**  
**Abridged Unaudited Financial Statements**  
**for the financial year ended 31 July 2025**

**Collon Pharmacy Limited**  
**CONTENTS**

	<b>Page</b>
Directors' Responsibilities Statement	3
Balance Sheet	4
Notes to the Financial Statements	5 - 7

## **Collon Pharmacy Limited**

# **DIRECTORS' RESPONSIBILITIES STATEMENT**

for the financial year ended 31 July 2025

The directors are responsible for preparing the Directors' Report and the financial statements in accordance with applicable Irish law and Generally Accepted Accounting Practice in Ireland including the accounting standards issued by the Financial Reporting Council.

Irish company law requires the directors to prepare financial statements for each financial year. Under that law, the directors have elected to prepare the financial statements in accordance with Irish Generally Accepted Accounting Practice (accounting standards issued by the Financial Reporting Council). Under company law, the directors must not approve the financial statements unless they are satisfied that they give a true and fair view of the assets, liabilities and financial position of the company as at the financial year end date and of the profit or loss of the company for the financial year and otherwise comply with the Companies Act 2014.

In preparing these financial statements, the directors are required to:

- select suitable accounting policies for the company financial statements and then apply them consistently;
- make judgements and accounting estimates that are reasonable and prudent;
- state whether the financial statements have been prepared in accordance with applicable accounting standards, identify those standards, and note the effect and the reasons for any material departure from those standards; and
- prepare the financial statements on the going concern basis unless it is inappropriate to presume that the company will continue in business.

The directors are responsible for ensuring that the company keeps or causes to be kept adequate accounting records which correctly explain and record the transactions of the company, enable at any time the assets, liabilities, financial position and profit or loss of the company to be determined with reasonable accuracy, enable them to ensure that the financial statements and Directors' Report comply with the Companies Act 2014. They are also responsible for safeguarding the assets of the company and hence for taking reasonable steps for the prevention and detection of fraud and other irregularities.

**Signed on behalf of the board**

**Anthony Fitzsimmons**  
Director

16 December 2025



**Emma Fitzsimmons**  
Director

16 December 2025



**Collon Pharmacy Limited**  
**BALANCE SHEET**  
as at 31 July 2025

	Notes	2025 €	2024 €
<b>Fixed Assets</b>			
Tangible assets	5	4,406	5,350
<b>Current Assets</b>			
Stocks	6	59,164	63,232
Debtors	7	91,404	81,432
Cash at bank and in hand		82,931	57,991
		233,499	202,655
<b>Creditors: amounts falling due within one year</b>	8	(81,620)	(83,899)
<b>Net Current Assets</b>		151,879	118,756
<b>Total Assets less Current Liabilities</b>		156,285	124,106
<b>Capital and Reserves</b>			
Called up share capital presented as equity		100	100
Retained earnings	9	156,185	124,006
<b>Shareholders' Funds</b>	10	156,285	124,106

We as Directors of Collon Pharmacy Limited, state that -

- (a) the company is availing itself of the exemption provided for by Chapter 15 of Part 6 of the Companies Act 2014,
- (b) the company is availing itself of the exemption on the grounds that the conditions specified in section 358 are satisfied,
- (c) the shareholders of the company have not served a notice on the company under section 334(1) in accordance with section 334(2),
- (d) we acknowledge the company's obligations under the Companies Act 2014, to keep adequate accounting records and prepare financial statements which give a true and fair view of the assets, liabilities and financial position of the company at the end of its financial year and of its profit or loss for such a financial year and to otherwise comply with the provisions of the Companies Act 2014 relating to financial statements so far as they are applicable to the company,
- (e) the company has relied on the specified exemption contained in section 352 Companies Act 2014. The company has done so on the grounds that the company is entitled to the benefit of that exemption as a small company and the abridged financial statements have been properly prepared in accordance with section 353 Companies Act 2014 and the small companies' regime.

Approved by the board on 16 December 2025 and signed on its behalf by:

Anthony Fitzsimmons  
Director



Emma Fitzsimmons  
Director



# Collon Pharmacy Limited

## NOTES TO THE ABRIDGED FINANCIAL STATEMENTS

for the financial year ended 31 July 2025

### 1. Summary of Significant Accounting Policies

#### Basis of preparation

The financial statements have been prepared on the going concern basis and in accordance with generally accepted accounting principles in Ireland and Irish statute comprising the Companies Act 2014. They comply with the financial reporting standards of the Financial Reporting Council.

The company qualifies as a small company as defined by section 280A of the Companies Act 2014 in respect of the financial year, and has applied the rules of the 'Small Companies Regime' in accordance with section 280C of the Companies Act 2014.

#### Accounting Convention

The financial statements are prepared under the historical cost convention.

#### Cash flow statement

The company has availed of the exemption in FRS 1 from the requirement to prepare a Cash Flow Statement because it is classified as a small company.

#### Turnover

Turnover comprises the invoice value of goods supplied by the company, exclusive of trade discounts and value added tax.

#### Tangible assets and depreciation

Tangible assets are stated at cost or at valuation, less accumulated depreciation. The charge to depreciation is calculated to write off the original cost or valuation of tangible assets, less their estimated residual value, over their expected useful lives as follows:

Fixtures, fittings and equipment	-	15% Straight line
----------------------------------	---	-------------------

The carrying values of tangible fixed assets are reviewed annually for impairment in periods if events or changes in circumstances indicate the carrying value may not be recoverable.

#### Stocks

Stocks are valued at the lower of cost and net realisable value. Stocks are determined on a first-in first-out basis. Cost comprises expenditure incurred in the normal course of business in bringing stocks to their present location and condition. Full provision is made for obsolete and slow moving items. Net realisable value comprises actual or estimated selling price (net of trade discounts) less all further costs to completion or to be incurred in marketing and selling.

#### Borrowing costs

Borrowing costs relating to the acquisition of assets are capitalised at the appropriate rate by adding them to the cost of assets being acquired. Investment income earned on the temporary investment of specific borrowings pending their expenditure on the assets is deducted from the borrowing costs eligible for capitalisation. All other borrowing costs are recognised in profit or loss in the period in which they are incurred.

#### Taxation

Current tax represents the amount expected to be paid or recovered in respect of taxable profits for the financial year and is calculated using the tax rates and laws that have been enacted or substantially enacted at the Balance Sheet date.

Deferred tax is recognised in respect of all timing differences that have originated but not reversed at the balance sheet date where transactions or events have occurred at that date that will result in an obligation to pay more tax in the future, or a right to pay less tax in the future. Timing differences are temporary differences between the company's taxable profits and its results as stated in the financial statements.

Deferred tax is measured on an undiscounted basis at the tax rates that are anticipated to apply in the periods in which the timing differences are expected to reverse, based on tax rates and laws that have been enacted or substantively enacted by the Balance Sheet date.

#### Foreign currencies

Monetary assets and liabilities denominated in foreign currencies are translated at the rates of exchange ruling at the balance sheet date. Transactions, during the year, which are denominated in foreign currencies are translated at the rates of exchange ruling at the date of the transaction. The resulting exchange differences are dealt with in the Profit and Loss Account.

## Collon Pharmacy Limited

# NOTES TO THE ABRIDGED FINANCIAL STATEMENTS

for the financial year ended 31 July 2025

### Ordinary share capital

The ordinary share capital of the company is presented as equity.

<b>2. Operating profit/(loss)</b>	<b>2025</b>	2024
	€	€
<b>Operating profit/(loss) is stated after charging:</b>		
Depreciation of tangible assets	<b>944</b>	944

### 3. Employees

The average monthly number of employees, including directors, during the financial year was 9, (2024 - 8).

	<b>2025</b>	2024
	Number	Number
Directors	2	2
Shop staff	7	6
	<b>9</b>	8

### 4. Tax on profit/(loss)

	<b>2025</b>	2024
	€	€

#### Analysis of charge in the financial year

#### Current tax:

Corporation tax	-	-
-----------------	---	---

No charge to tax arises due to tax losses incurred.

### 5. Tangible assets

	<b>Fixtures, fittings and equipment</b>	<b>Total</b>
	€	€
<b>Cost</b>		
At 1 August 2024	48,973	48,973
At 31 July 2025	48,973	48,973
<b>Depreciation</b>		
At 1 August 2024	43,623	43,623
Charge for the financial year	944	944
At 31 July 2025	44,567	44,567
<b>Net book value</b>		
At 31 July 2025	<b>4,406</b>	<b>4,406</b>
At 31 July 2024	5,350	5,350

### 6. Stocks

	<b>2025</b>	2024
	€	€
Finished goods and goods for resale	<b>59,164</b>	63,232

The replacement cost of stock did not differ significantly from the figures shown.

## Collon Pharmacy Limited

# NOTES TO THE ABRIDGED FINANCIAL STATEMENTS

for the financial year ended 31 July 2025

<b>7. Debtors</b>	<b>2025</b>	<b>2024</b>
	€	€
Trade debtors	43,976	39,696
Taxation	33,788	30,669
Prepayments	13,640	11,067
	<u>91,404</u>	<u>81,432</u>
<b>8. Creditors</b>	<b>2025</b>	<b>2024</b>
<b>Amounts falling due within one year</b>	<b>€</b>	<b>€</b>
Amounts owed to credit institutions	600	1,010
Trade creditors	63,976	65,495
Taxation	2,686	2,586
Directors' current accounts (Note 12)	232	232
Accruals	14,126	14,576
	<u>81,620</u>	<u>83,899</u>
<b>9. Profit and loss account</b>	<b>2025</b>	<b>2024</b>
	€	€
At 1 August 2024	124,006	135,870
Profit/(loss) for the financial year	32,179	(11,864)
At 31 July 2025	<u>156,185</u>	<u>124,006</u>
<b>10. Reconciliation of movements in shareholders' funds</b>	<b>2025</b>	<b>2024</b>
	€	€
Profit/(loss) for the financial year	32,179	(11,864)
Opening shareholders' funds	124,106	135,970
Closing shareholders' funds	<u>156,285</u>	<u>124,106</u>
<b>11. Capital commitments</b>		
The company had no material capital commitments at the financial year-ended 31 July 2025.		
<b>12. Directors' remuneration and transactions</b>	<b>2025</b>	<b>2024</b>
	€	€
Remuneration	86,307	94,832
Pension contributions	115,846	100,000
	<u>202,153</u>	<u>194,832</u>
<b>13. Post-Balance Sheet Events</b>		
No events have adversely affected the operating and financial performance of the company.		
<b>14. Approval of financial statements</b>		
The financial statements were approved and authorised for issue by the board of directors on 16 December 2025.		